Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
November 6, 2026

Alfasigma receives EC’s expanded approval for filgotinib to treat axSpA

Alfasigma has received expanded approval from the European Commission (EC) for Jyseleca (filgotinib) to treat adult patients living with active axial spondyloarthritis (axSpA).

axSpA typically emerges in patients in their 30s, affecting the axial skeleton and causing persistent back pain. Credit: PeopleImages / Shutterstock.com.